

BIOCRYST PHARMACEUTICALS INC

Form 8-K

August 09, 2005

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report: August 9, 2005

BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or other jurisdiction
of incorporation)

000-23186
(Commission
File Number)

62-1413174
(IRS Employer
Identification #)

2190 Parkway Lake Drive, Birmingham, Alabama 35244
(Address of Principal Executive Office)

(205) 444-4600
(Registrant's telephone number, including area code)

Item 8.01 Other Events.

On August 9, 2005, Registrant issued a press release announcing the initiation of a Phase I pharmacokinetic clinical trial with intravenous/oral Fodosine in healthy volunteers. The press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.

Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to Registrant's Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrant's Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

Item 9.01 Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated August 9, 2005 entitled BioCryst Advances Lead Product Program; Initiates Intravenous/Oral Pharmacokinetic Clinical Trial of Fodosine in Healthy Volunteers to Support Pivotal Trial .

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated August 9, 2005 entitled BioCryst Advances Lead Product Program; Initiates Intravenous/Oral Pharmacokinetic Clinical Trial of Fodosine in Healthy Volunteers to Support Pivotal Trial .